Table 1 Prevalence of PD-L1 expression by artificial intelligence-powered and manual scoring.

From: Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab

 

Evaluable samples for AI-powered assessment—no.

Prevalence—no. (%)

P value

AI-powereda

Manuala

1% cutoff

  

<1%

≥1%

<1%

≥1%

 

CheckMate 057 (NSCLC)

194

19 (9.8)

175 (90.2)

95 (49.0)

99 (51.0)

<0.01

CheckMate 275 (UC)

241

75 (30.1)

166 (68.9)

128 (53.1)

113 (46.8)

<0.01

CheckMate 067 (MEL; NIVO)

265

91 (34.3)

174 (65.7)

104 (39.3)

161 (60.8)

0.28

CheckMate 067 (MEL; NIVO + IPI)

262

101 (38.6)

161 (61.5)

117 (44.7)

145 (55.3)

0.18

CheckMate 238 (MEL)

377

70 (18.6)

307 (81.4)

118 (31.3)

259 (68.7)

<0.01

CheckMate 141 (SCCHN)

153

88 (57.5)

65 (42.5)

69 (45.1)

84 (54.9)

0.04

5% cutoff

  

<5%

≥5%

<5%

≥5%

 

CheckMate 026 (NSCLC)

254

21 (8.3)

233 (91.7)

58 (22.8)

196 (77.2)

<0.01

CheckMate 057 (NSCLC)

194

84 (43.3)

110 (56.7)

117 (60.3)

77 (39.7)

<0.01

CheckMate 275 (UC)

241

151 (62.7)

90 (37.3)

167 (69.3)

74 (30.7)

0.15

CheckMate 067 (MEL; NIVO)

265

162 (61.1)

103 (38.9)

189 (71.3)

76 (28.7)

0.02

CheckMate 067 (MEL; NIVO + IPI)

262

170 (64.9)

92 (35.1)

197 (75.2)

65 (24.8)

0.01

CheckMate 238 (MEL)

377

143 (37.9)

234 (62.1)

238 (63.1)

139 (36.9)

<0.01

CheckMate 141 (SCCHN)

153

109 (71.2)

44 (28.8)

101 (66.0)

52 (34.0)

0.39